Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Equity (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Return on Equity readings, the most recent being 0.06% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 16.0% year-over-year to 0.06%, compared with a TTM value of 0.06% through Dec 2025, up 16.0%, and an annual FY2025 reading of 0.07%, up 19.0% over the prior year.
  • Return on Equity hit 0.06% in Q4 2025 for Apellis Pharmaceuticals, down from 0.79% in the prior quarter.
  • The five-year high for Return on Equity was 9.36% in Q2 2021, with the low at 4.46% in Q4 2021.
  • Median Return on Equity over the past 5 years was 0.81% (2022), compared with a mean of 0.41%.
  • The sharpest move saw Return on Equity crashed -988bps in 2022, then skyrocketed 215bps in 2024.
  • Year by year, Return on Equity stood at 4.46% in 2021, then soared by 46bps to 2.39% in 2022, then grew by 6bps to 2.25% in 2023, then soared by 95bps to 0.1% in 2024, then soared by 157bps to 0.06% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.06%, 0.79%, and 0.34% for Q4 2025, Q3 2025, and Q2 2025 respectively.